Hyloris Pharmaceuticals SA announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has signed an exclusive license and distribution agreement with Hikma Pharmaceuticals (“Hikma”) for the U.S. commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain. Under the terms of the agreement with AFT, Hikma will have exclusive rights for the sales, marketing, and distribution of Maxigesic IV in the U.S. Hyloris is eligible to receive $4 million in regulatory based milestones as well as commercial milestones plus a share of any additional product-related income received by AFT in the U.S.